Skip to content
10-Q

Quarterly Report

REGENERX BIOPHARMACEUTICALS, INC.

0001410578-22-001705

← back to feed
Filed
May 16, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · May 6, 2022 143.55M sh
Cash And Equivalents Q1 2022 · Mar 31, 2022 $925.3K
Cash And Equivalents Q1 2022 · Dec 31, 2021 $1.23M
Current Liabilities Q1 2022 · Mar 31, 2022 $403.03K
Current Liabilities Q1 2022 · Dec 31, 2021 $429.93K
Total Liabilities Q1 2022 · Mar 31, 2022 $3.53M
Total Liabilities Q1 2022 · Dec 31, 2021 $3.51M
Current Assets Q1 2022 · Mar 31, 2022 $938.57K
Current Assets Q1 2022 · Dec 31, 2021 $1.25M
Total Assets Q1 2022 · Mar 31, 2022 $960.53K
Total Assets Q1 2022 · Dec 31, 2021 $1.28M
Rd Expense Q1 2022 · Mar 31, 2022 $0
Rd Expense Q1 2022 · Mar 31, 2021 $488
Shares Diluted Q1 2022 · Mar 31, 2021 133.52M sh
Operating Cash Flow Q1 2022 · Mar 31, 2021 −$242.33K
Stockholders Equity Q1 2022 · Mar 31, 2021 −$3.12M
Stockholders Equity Q1 2022 · Dec 31, 2020 −$2.82M
Eps Diluted Q1 2022 · Mar 31, 2021 $0.00
Eps Basic Q1 2022 · Mar 31, 2021 $0.00
Sga Expense Q1 2022 · Mar 31, 2021 $318.12K
Net Income Q1 2022 · Mar 31, 2021 −$379.69K
Operating Income Q1 2022 · Mar 31, 2021 −$299.42K
Revenue Q1 2022 · Mar 31, 2021 $19.19K